Format

Send to

Choose Destination
J Allergy Clin Immunol. 2017 Jan;139(1):173-181.e8. doi: 10.1016/j.jaci.2016.05.027. Epub 2016 Aug 10.

Early oral immunotherapy in peanut-allergic preschool children is safe and highly effective.

Author information

1
University of North Carolina-Chapel Hill, Chapel Hill, NC.
2
Duke University School of Medicine, Durham, NC.
3
Johns Hopkins School of Medicine, Baltimore, Md.
4
Massachusetts General Hospital, Boston, Mass.
5
Mayo Clinic, Scottsdale, Ariz.
6
University of North Carolina-Chapel Hill, Chapel Hill, NC. Electronic address: wesley.burks@unc.edu.

Abstract

BACKGROUND:

Oral immunotherapy (OIT) is an effective experimental food allergy treatment that is limited by treatment withdrawal and the frequent reversibility of desensitization if interrupted. Newly diagnosed preschool children may have clinical and immunological characteristics more amenable to treatment.

OBJECTIVE:

We sought to test the safety, effectiveness, and feasibility of early OIT (E-OIT) in the treatment of peanut allergy.

METHODS:

We enrolled 40 children aged 9 to 36 months with suspected or known peanut allergy. Qualifying subjects reacted to peanut during an entry food challenge and were block-randomized 1:1 to receive E-OIT at goal maintenance doses of 300 or 3000 mg/d in a double-blinded fashion. The primary end point, sustained unresponsiveness at 4 weeks after stopping early intervention oral immunotherapy (4-SU), was assessed by double-blinded, placebo-controlled food challenge either upon achieving 4 prespecified criteria, or after 3 maintenance years. Peanut-specific immune responses were serially analyzed. Outcomes were compared with 154 matched standard-care controls.

RESULTS:

Of 40 consented subjects, 3 (7.5%) did not qualify. Overall, 29 of 37 (78%) in the intent-to-treat analysis achieved 4-SU (300-mg arm, 17 of 20 [85%]; 3000 mg, 12 of 17 [71%], P = .43) over a median of 29 months. Per-protocol, the overall proportion achieving 4-SU was 29 of 32 (91%). Peanut-specific IgE levels significantly declined in E-OIT-treated children, who were 19 times more likely to successfully consume dietary peanut than matched standard-care controls, in whom peanut-specific IgE levels significantly increased (relative risk, 19.42; 95% CI, 8.7-43.7; P < .001). Allergic side effects during E-OIT were common but all were mild to moderate.

CONCLUSIONS:

At both doses tested, E-OIT had an acceptable safety profile and was highly successful in rapidly suppressing allergic immune responses and achieving safe dietary reintroduction.

KEYWORDS:

Oral immunotherapy; desensitization; early intervention; peanut allergy; randomized clinical trial; sustained unresponsiveness

PMID:
27522159
PMCID:
PMC5222765
DOI:
10.1016/j.jaci.2016.05.027
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center